live sessions
MST:
Mountain Standard Time
MST
:
Mountain Standard Time
Wednesday (February 25) Sessions
Live Now:
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Upcoming:
FEB25
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
FEB25
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
Previous:
FEB25
8:30 AMto9:30 AMMST
12:00 PMto5:00 PMMST
Wednesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Wednesday
Wafaa M. El-Sadr
Columbia University, New York, NY, USA
8:35 AM8:35 AM
34 - Successes in HIV-1 Vaccine Design: Accelerating Completion of One of Science's Most Difficult Vaccines
Kevin O. Saunders
Duke Human Vaccine Institute, Durham, NC, USA
9:05 AM9:05 AM
35 - Tuberculosis in Children and Adolescents: From Neglect to Action
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Manipulating the HIV Immune Response for Prevention and Treatment
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
166 - Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
10:13 AM10:13 AM
167 - Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
168 - In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
10:29 AM10:29 AM
169 - Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
170 - Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
11:13 AM11:13 AM
171 - A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:21 AM11:21 AM
172 - Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:29 AM11:29 AM
173 - Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART
Mirko Paiardini
Emory University, Atlanta, GA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Extending the Reach: Long-Acting Antiviral and Novel Delivery
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
174 - Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable InSTI
Samir Gupta
Indiana University Health, Indianapolis, IN, USA
10:13 AM10:13 AM
175 - Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing
Nilay Thakkar
GSK plc, Collegeville, PA, USA
10:21 AM10:21 AM
176 - Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back
GSK plc, Collegeville, PA, USA
10:29 AM10:29 AM
177 - DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study
Juergen K. Rockstroh
Bonn University Hospital, Bonn, Germany
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
178 - Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study
Charlotte-Paige Rolle
Orlando Immunology Center, Orlando, FL, USA
11:13 AM11:13 AM
179 - Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial
Trevor A. Crowell
Henry M Jackson Foundation, Bethesda, MD, USA
11:21 AM11:21 AM
180 - Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks
Pablo Tebas
University of Pennsylvania, Philadelphia, PA, USA
11:29 AM11:29 AM
181 - Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1
Chloe M. Orkin
Queen Mary University of London, London, UK
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
From Good to Great: Advancing Treatment and Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
182 - HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
10:13 AM10:13 AM
183 - Impact of Person-Centered Care Intervention on HIV Treatment Failure Response in Zambia
Kombatende Sikombe
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
10:21 AM10:21 AM
184 - The START mHealth Application Reduces Risk of Virologic Rebound in Men With HIV Who Use Stimulants
Adam W. Carrico
Florida International University, Miami, FL, USA
10:29 AM10:29 AM
185 - Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma
Kathleen J. Sikkema
Columbia University, New York, NY, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
186 - SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa
Ruanne V. Barnabas
Massachusetts General Hospital, Boston, MA, USA
11:13 AM11:13 AM
187 - Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation
Deborah Hoege
Georgetown University, Washington, DC, USA
11:21 AM11:21 AM
188 - Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe
Constancia C. Watadzaushe
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
11:29 AM11:29 AM
189 - Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial
Chris T. Longenecker
University of Washington, Seattle, WA, USA
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
10:00 AMto12:00 PMMST
12:00 PMto5:00 PMMST
Partners, Pills, and Penicillin: Progress in Prevention
10:00 AM10:00 AM
Introduction of Speakers (Part 1)
10:05 AM10:05 AM
190 - Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25
Chase A. Cannon
University of Washington, Seattle, WA, USA
10:13 AM10:13 AM
191 - HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study
Melissa Schnure
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:21 AM10:21 AM
192 - HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico
Sari L. Reisner
University of Michigan, Ann Arbor, MI, USA
10:29 AM10:29 AM
193 - Awareness of Sex Partners’ HIV Status and Risk of HIV Acquisition: Rakai, Uganda
Victor Ssempijja
Leidos Biomedical Research, Inc, Frederick, MD, USA
10:37 AM10:37 AM
Questions and Answers (Part 1)
11:00 AM11:00 AM
Introduction of Speakers (Part 2)
11:05 AM11:05 AM
194 - Comparative Effectiveness of 3 Benzathine Penicillin G-Based Regimens in PWH With Early Syphilis
Kai Hsiang Chen
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
11:13 AM11:13 AM
195 - Early Syphilis and HIV Among Adolescents: United States, 20142-023
Daniel Gore
Centers for Disease Control and Prevention, Atlanta, GA, USA
11:21 AM11:21 AM
196 - Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina
Assistance Publique – Hôpitaux de Paris, Paris, France
11:29 AM11:29 AM
197 - Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men
Kate L. Seib
Griffith University, Southport, Australia
11:37 AM11:37 AM
Questions and Answers (Part 2)
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Harnessing B-Cells and Antibodies for HIV Control
1:30 PM1:30 PM
Session Overview
Nicole A. Doria-Rose
Vaccine Research Center, Bethesda, MD, USA
1:34 PM1:34 PM
294 - AAV-Delivered Antibody Reaches Mucosal Sites and Protects Against SHIV Infection in Rhesus Macaques
Luanna E. L. Vidal
University of Miami, Miami, FL, USA
1:38 PM1:38 PM
295 - Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
1:42 PM1:42 PM
296 - Antigen-Specific Memory B Cells of Extrafollicular Origin May Contribute to ART-Free HIV Control
Elif Cakan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
1:46 PM1:46 PM
297 - Evidence of Immune Activation During bNAb-Mediated HIV Suppression Following ATI
Julia A. Wagner
University of California San Francisco, San Francisco, CA, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Tuberculosis: Innovative Screening and Diagnostic Approaches
1:30 PM1:30 PM
Session Overview
Yukari C. Manabe
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1:34 PM1:34 PM
773 - Efficiency of Portable Chest X-Ray Compared to Symptom-Based TB Screening in Southwest Nigeria
Aderonke V. Agbaje
Institute of Human Virology Nigeria, Abuja, Nigeria
1:38 PM1:38 PM
774 - High Prevalence of Asymptomatic Tuberculosis in an African Cohort of People With HIV (CoVPN 3008-TB)
Asa Tapley
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
775 - The Case for Routine Testing and Empiric Treatment of TB Meningitis in High HIV-Prevalence Settings
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
1:46 PM1:46 PM
776 - Very Promising New Urinary LAM Assay for Tuberculosis Diagnosis in Children
Adeline Riondel
French National Institute of Health and Medical Research (Inserm), Paris, France
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Advancing Mental Health for Youth With HIV
1:30 PM1:30 PM
Session Overview
Claude A. Mellins
Columbia University Irving Medical Center, New York, NY, USA
1:34 PM1:34 PM
871 - Depression, Anxiety, and Viral Suppression Among Adolescents and Young Adults in 9 African Countries
Jiayu Wang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1:38 PM1:38 PM
872 - Implementation of a Mental Health Intervention for Youth With HIV in Kenya
Pamela Kohler
University of Washington, Seattle, WA, USA
1:42 PM1:42 PM
874 - Primary Outcomes of SYV (Voice of Youth) Mental Health Intervention: A Randomized Trial in Tanzania
Dorothy Dow
Duke University Medical Center, Durham, NC, USA
1:46 PM1:46 PM
873 - Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV
Geri Donenberg
University of Illinois at Chicago Center for Dissemination and Implementation Science, Chicago, IL, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
1:30 PMto2:30 PMMST
12:00 PMto5:00 PMMST
Some Assembly Required: Self-Blood Collection and Testing
1:30 PM1:30 PM
Session Overview
Michelle Rodolph
World Health Organization, Geneva, Switzerland
1:34 PM1:34 PM
975 - Identifying Where HIV Self-Screening Has Greatest Impact: Analysis of Routine Data in South Africa
Alexandra de Nooy
Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
1:38 PM1:38 PM
974 - HIV Self-Testing by Motorcycle-Taxi Drivers: A Novel Approach for Case Detection in Kampala, Uganda
Edith Namulema
Mengo Hospital, Kampala, Uganda
1:42 PM1:42 PM
977 - Virtual Submission of HIV Viral Load in EPI-LoVE, a Digital Cohort of People Living With HIV in US
Pamina M. Gorbach
University of California Los Angeles, Los Angeles, CA, USA
1:46 PM1:46 PM
976 - Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms
David Closs
Friends for All, Memphis, TN, USA
1:50 PM1:50 PM
Discussion With Audience Questions and Answers
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Masters of Immunity: The Many Faces of T Cells
4:00 PM4:00 PM
36 - Nonconventional T Cells: Functional Shape Shifters and Conductors of Cytokine Orchestras That Dance With Herpesviruses in People With HIV
Jennifer Snyder-Cappione
Boston University, Boston, MA, USA
4:20 PM4:20 PM
37 - The T-Cell Identity: Conventional T Cells in Action
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
4:40 PM4:40 PM
38 - Engineering T Cells: Improving on Nature
Anjie Zhen
University of California Los Angeles, Los Angeles, CA, USA
5:00 PM5:00 PM
Questions and Answers
Pamela J. Skinner
University of Minnesota, Minneapolis, MN, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Time for a Paradigm Shift for Young Pregnant and Breastfeeding Cisgender Women
4:00 PM4:00 PM
39 - HIV Prevention and Treatment Among Young Mothers: Dynamics of Biologic, Psychosocial, and Structural Determinants Across the Life Course
Elona Toska
University of Cape Town, Cape Town, South Africa
4:20 PM4:20 PM
40 - Continuity of Care During Pregnancy and Postpartum
Aleny Couto
Ministry of Health of Mozambique, Maputo, Mozambique
4:40 PM4:40 PM
41 - Ethical and Regulatory System Changes for the Inclusion of Pregnant Women in HIV Research and Development
Cordelia Katureebe
Ministry of Health Uganda, Kampala, Uganda
5:00 PM5:00 PM
Questions and Answers
Lynn T. Matthews
Yale University, New Haven, CT, USA
FEB25
4:00 PMto5:30 PMMST
12:00 PMto5:00 PMMST
Hot Takes on the Clinical Highlights From CROI 2026
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Joseph J. Eron, Jr
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Fatima Kakkar
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Chloe M. Orkin
Queen Mary University of London, London, UK
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Deborah Persaud
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4:00 PM4:00 PM
42 - Panel Discussion Plus Questions and Answers from the Audience
Paul E. Sax
Brigham and Women's Hospital, Boston, MA, USA
FEB25
10:30 PMto10:45 PMMST
12:00 PMto5:00 PMMST
Test Workshop Session 6
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestLastName 1
Institution 1
